Screening and pre-emptive isolation of at-risk patients are important aspects of the Danish approach to the prevention of meticillin-resistant Staphylococcus aureus (MRSA) infection, but screening with conventional culture can take up to 3 days for results to become available with attendant costs and disadvantages of prolonged isolation. We sought to evaluate the accuracy, time to availability of results and potential economic benefits of two next-generation MRSA screening assays, Xpert MRSA Gen 3 (GX MRSA) and BD MAX MRSA XT, in a setting of a consolidated laboratory serving a number of hospitals with a low prevalence of MRSA and using enrichment culture as a reference method. Four hundred and forty-seven screening samples together with 49 previously positive MRSA samples were evaluated. Xpert MRSA Gen 3 demonstrated sensitivity, specificity, positive predictive value and negative predictive value of 88.2, 97.9, 62.5 and 99.5 %, respectively, and for BD MAX MRSA XT, they were 88.2, 97.4, 57.7 and 99.5 %, respectively. Hands-on time was 8.8 and 21.6 min, respectively, for the Xpert MRSA Gen 3 and BD MAX MRSA XT PCR assays when five samples were handled simultaneously. The mean laboratory turnaround time was 2.9 (1-6) hours for the Xpert MRSA Gen 3 assay, 6.5 (2-46) hours for BD MAX MRSA XT and 49.6 (42-122) hours for enriched culture. Despite laboratory costs being higher for the rapid PCR assays, when the costs of isolation are taken into account, the assays offer the potential for significant cost savings.
INTRODUCTION
Meticillin-resistant Staphylococcus aureus (MRSA) infections represent a serious challenge for healthcare institutions. In Denmark, in 2014, MRSA cases increased by 42 % compared to 2013, and the number of new cases was almost five times higher than in 2007. Despite this, the prevalence of invasive MRSA infections in Denmark remains low, with only 2.9 % of S. aureus bacteraemia infections caused by MRSA in 2014, compared to rates above 10 % in most other countries reporting to the European Antimicrobial Surveillance Network (http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx).
Screening for MRSA carriage is a significant component of the Danish strategy to combat MRSA and maintain low infection rates. Danish national guidelines on preventing the spread of MRSA require patients with risk factors to be placed in single rooms with contact precautions from admission until a negative MRSA screen (swabs from nostrils, throat, perineum and any clinical sites) is available, which may take up to 2 to 3 days using conventional culture.
Molecular techniques have the ability to produce results that are accurate and available in a much speedier time frame than conventional culture. Commercial assays for MRSA screening have been available for some time; however, these have been challenged by the constantly increasing molecular diversity in staphylococcal cassette chromosome mec (SCCmec), the mobile genetic element that carries the mecA gene. In recent years, an MRSA clone with clonal complex (CC) 398, which originated in the community and is associated with exposure to livestock, has emerged in different countries worldwide, including The Netherlands and Denmark [1] , and it is important for a screening method to be able to detect this increasingly prevalent clone. Furthermore, MRSA clones harbouring the divergent mecA gene, designated mecC, pose a diagnostic problem with the potential to be misdiagnosed as meticillin-sensitive S. aureus [2] .
Two new-generation MRSA screening assays, Xpert MRSA Gen 3 (Cepheid) (GX MRSA) and BD MAX MRSA XT (Becton Dickinson) (MAX MRSA), have integrated the detection of the mecC gene into the assays [3, 4] . Both tests rely on the same principle and detect the mecA/C gene as well as the presence of the junction between the SCCmec element and the S. aureus chromosome [5] .
The aims of this study were to evaluate the accuracy, time to availability of results and potential economic impact of these two commercially available MRSA screening assays in a routine diagnostic setting in a low-prevalence MRSA country. Enriched culture was used as reference method. A further objective was to validate the utility of the eSwab liquid transport medium (Copan Diagnostica), as this system had not previously been validated for these assays at the time the study was performed.
METHODS
Our organization is served by an off-site laboratory covering six hospital sites as well as community services. Samples are transported to the laboratory at 08:00 and 16:00 daily.
During the period from December 2014 to March 2015, 447 MRSA screening samples were collected in eSwab liquid transport system from 145 hospital inpatients and tested with the Xpert MRSA Gen 3 PCR (GX MRSA) and BD MAX MRSA XT PCR (MAX MRSA) assays. Selective enrichment in tryptic soy broth (Department of Clinical Microbiology, Herlev Hospital, Denmark) followed by plating on CHROMagar MRSA (bioM erieux) and 5 % Danish blood agar (SSI Diagnostica) served as the reference method [6, 7] .
To evaluate the ability of the assays to detect common MRSA types prevalent in Denmark, an additional 49 previously culture-positive randomly selected MRSA swabs (from both inpatients and community setting) were also tested by GX MRSA and MAX MRSA assays directly from the original eSwab liquid medium stored at +4 C for 3 to 10 days. These swabs include 17 nasal, 21 throat and 2 perineum swabs and 9 from other locations.
The amount of material used for the analysis was based on the manufacturers' recommendations. For GX MRSA, 100 µl of eSwab liquid medium was added to the elution reagent vial. Analysis on the GeneXpert Infinity (Cepheid) was started within 30 min after sample preparation. For MAX MRSA, 250 µl of eSwab liquid medium was transferred to the sample buffer tube, followed by vortexing for 1 min. The analysis was started on the BD MAX (Becton Dickinson) as soon as the instrument was available (although within 4 h). The samples in SBT were stored at 4 C before loading onto BD MAX machine. The remaining procedures were performed according to the manufacturers' instructions with automated result interpretation. A manual examination of the raw data [amplification curves, cycle threshold (Ct) values and level of fluorescence] was performed for GX MRSA as earlier described [8] . Manual evaluation of amplification curves on the BD MAX for an in vitro diagnostic-approved kit was not possible because fluorescence level and Ct value were not shown.
For enriched culture, 100 µl of eSwab liquid medium was transferred to 2.5 ml tryptic soy broth. After incubation at 35 to 37 C for 16 to 18 h, 10 µl of enriched culture was plated onto MRSA CHROMagar and 5 % Danish blood agar with a cefoxitin disc (Oxoid). After 16 to 24 h incubation at 35 to 37 C, colonies with characteristic growth on CHROM-agar or 5 % Danish blood agar (within the cefoxitin zone) were tested with a Staphaurex Plus latex agglutination test (Remel) to identify S. aureus. Colonies identified as S. aureus were analysed by an agglutination test for penicillin-binding protein 2a (bioM erieux) for meticillin resistance. All positive MRSA strains were sent to the national reference laboratory at the Statens Serum Institut for confirmation by PCR for mecA/C and typed for spa types and CC.
Samples with discordant results were repeated in all three analyses. For GX MRSA, analysis was repeated using 250 µl sample (if there was enough material). For samples with false-negative PCR results, MRSA strains from these samples were cultured on 5 % Danish blood agar, and bacterial suspensions in 0.9 % NaCl at 1Â10 4 c.f.u./ml were prepared for GX MRSA and MAX MRSA assays.
The following data were retrieved from the laboratory information system (LIS): MRSA risk factors, time of sampling, sample arrival at laboratory, sample registration in LIS, sample arrival in PCR laboratory, analysis start and finish time and result registration in LIS.
Laboratory turnaround time (LTAT) was defined as the time between sample registration and the result being available on the instrument in the laboratory. Technical handson time for one and five samples was measured for both GX MRSA and MAX MRSA on a subset of samples on one occasion by observing with a stop clock.
For each method, LTAT was converted from hours to days (a day being 24 h). The extra cost for each patient in isolation was assumed to be approximately 3000 DKK (e400) per day (Report on MRSA-economy, Danish Health Authority, March 2006). Cost per reportable result included list prices for the assay, specific reagents and consumables and the technician salary. The potential annual savings by using rapid PCR-based methods were calculated based on the number of MRSA screening samples taken from in-hospital patients from Region Zealand in 2014.
RESULTS

Performance characteristics
A total of 447 samples were prospectively collected/tested: 154 nasal, 145 throat, 110 perineum and 110 wound swabs. Twenty-two were from other clinical sites. Table 1 shows the sample distribution according to MRSA risk factors. In this cohort, 74 of 245 (51 %) patients required isolation on admission until a negative MRSA screening result was available. These patients either had previous MRSA colonization or had been hospitalized in countries other than the Nordic region. Of the 49 previously known culture-positive samples, there were 17 nasal, 19 throat, 2 perineum and 5 wound swabs and 6 from other sites.
Seventeen (3.8 %) of the 447 samples from 11 (7.6 %) patients were positive by enriched culture (Table 1) . spa typing and CC testing identified 10 samples as t034-CC398, 4 as t002-CC5, 1 as t223-CC22, 1 as t004-CC45 and 1 as t1705-CC8. The first three types are commonly circulating clones in Denmark, while the latter two are less common, although previously reported from Denmark. Among the 74 pre-emptively isolated patients, 5 were positive for MRSA (6.8 %).
The sensitivity for GX MRSA and MAX MRSA was 88.2 % for both methods, while the specificity was 97.9 % and 97.4 %, respectively. The positive predictive value was 62.5 and 57.7 % for GX MRSA and MAX MRSA, respectively, while the negative predictive value (NPV) was 99.5 % for both assays. After manual examination of raw data, the sensitivity for GX MRSA could be increased to 94.1 % by extending the Ct value (Table 2) . Our results also suggest that the eSwab is an acceptable system for collection and transport.
Fifteen of the 17 culture-positive samples were positive by both PCR assays. Two samples with t002-CC5 from one patient (an ear and a throat swab) were negative in both assays. The third screening swab from this patient (nasal) taken at the same time was positive for MRSA by all three methods (Table 3) .
Among culture-negative samples, 9 and 11 samples were positive with the GX MRSA and MAX MRSA assays, respectively (Table 2) . Discordant results and attempts to resolve discrepancies are summarized in Table 3 .
Of the 49 previously known positive samples, one gave a false-negative result by GX MRSA, and three gave a falsenegative result by MAX MRSA. CC and spa type distribution of these samples (covering 21 different spa types) is shown in Table 4 .
Turnaround times
The technical hands-on time for GX MRSA and MAX MRSA were 3.2 and 16 min, respectively, when one sample was handled, and 8.8 and 21.6 min, respectively, when five samples were handled simultaneously. The instrument analysis time was 61 min for GX MRSA for each sample, while it was 100 to 136 min per run for MAX MRSA depending on the number of samples.
The mean LTAT was 2.9 (1-6) hours for the GX MRSA assay, 6.5 (2-46) hours for MAX MRSA and 49.6 (42-122) hours for enriched culture.
The mean sample transport time (from sample collection to sample registration in LIS) was 15.3 h. Only 147 of 447 samples arrived in the laboratory the same day as the sample was taken compared to 285 of 447 samples that arrived in the laboratory the following day.
In Region Zealand in Denmark, 2500 MRSA screening samples were from 837 patients who were admitted to the hospital during 2014. Based on the data in this study, we assumed that 51 % of the patients needed pre-emptive isolation (427 patients); of these, 93 % had negative screening results (397 patients). The extra cost for each patient in isolation was assumed to be approximately 3000 DKK (e400) per day. One day of unnecessary isolation for 397 patients cost e158 800. The cost per reportable result for GX MRSA was e42 and, for MAX MRSA, was e36 assuming seven samples per run. The annual cost to run GX MRSA (2500 samples) was e105 725 and, to run BD MAX (2500 samples), was e90 143.
Considering 1 day as 24 h, the average LTAT for enriched culture was converted to 2.06 days; GX MRSA, to 0.12 days; and MAX MRSA, to 0.27 days. When the LTAT using the analysis finish time on the instrument as endpoint was applied, the net savings would be e202 347 and e194 067 for GX MRSA and MAX MRSA, respectively.
DISCUSSION
Generally, GX MRSA and MAX MRSA demonstrated similar performance in this study. The sensitivity was 88.2 % for both methods, and the specificity was similar (97.9 % for GX MRSA and 97.4 % for MAX MRSA). These results are in contrast to a recent study where Lepainteur et al. [] compared GX MRSA and MAX MRSA to enriched culture in 119 prospective swabs and found GX MRSA to have superior sensitivity and specificity to MAX MRSA3.
One possible explanation for this difference may be that the Lepainteur study was performed in selective high-prevalence wards in a French tertiary care centre, whereas the samples in our study came from six different secondary hospitals in Region Zealand in Denmark, all with a low prevalence of MRSA carriage.
In our study, LTAT was based on time registered prospectively for each sample which reflected the reality of our setting where a single laboratory serves a number of hospitals with limited transport arrangements. We believe that this reflects the situation in many European laboratories where consolidated laboratories serving a number of inpatient and community settings are a common organizational structure. The prolonged LTAT of MAX MRSA compared to GX MRSA reflects the batch testing required for MAX MRSA assay.
Both molecular assays performed well on all the different spa types including the increasingly prevalent CC398 and emerging mecC harbouring strains. Our results suggest that MAX MRSA may have some limitations with regard to detecting SCCmec junction variants. Both GX MRSA and MAX MRSA reported false-negative results in two samples (t002-CC5) from one patient in the prospective cohort.
In the retrospective collection, one sample (t688-CC5) was a false negative in both GX MRSA and MAX MRSA. A bacterial suspension at 1Â10 4 c.f.u./ml was prepared from the MRSA strain isolated by culture. GX MRSA was positive, while MAX MRSA remained negative. A further two samples (t127-CC1) from one patient from the retrospective collection were false negative only by MAX MRSA, and the result remained negative after testing using bacterial suspension.
Because of the constantly changing epidemiology in MRSA genetic types, the molecular assays designed several years earlier could present less sensitive results [9, 10] . The newer-generation MRSA assays have extended the primer combination to more SCCmec junction types according to the global epidemiology, including the increasing livestockassociated types and those harbouring mecC variant [3, 4] .
In this study, 19 livestock-associated type CC398 (10 from the prospective samples) were represented. All these were correctly detected by both methods. From the retrospective collection, one sample with t843 and one with t1535 (both spa types are known to harbour mecC variant) were detected by both methods. A common clone in Denmark, spa t024-sequence type 8-IVa, was not present among the test populations in this study. Bartels et al. [9] reported that BD GeneOhm did not detect this clone. Therefore, two t024 MRSA isolates from two patients were cultured, and bacterial suspensions in 0.9 % NaCl were prepared at 1Â10 4 c.f.u./ml. GX MRSA and MAX MRSA both correctly identified MRSA in these suspensions.
A potential drawback of using PCR assays in low-prevalence settings may be an increase in the number of false-positive results where PCR is used as a stand-alone method. GX MRSA reported nine samples as false positive; and MAX MRSA, 11 samples. Similar false-positive results were reported by Blanc et al. [11] . Other studies have demonstrated molecular methods to be more sensitive than culture-based methods [4, 12, 13] . One sample that was culture negative showed a positive result from both GX MRSA and MAX MRSA. The clinical information for this patient revealed that the patient was receiving topical treatment prior to sampling, while samples taken 2 weeks earlier and 2 weeks later were all MRSA positive in culture. Therefore, we conclude that, in this case, the culture was falsely negative due to the antimicrobial treatment.
In an area with a low prevalence of MRSA such as Denmark, screening assays with a high NPV are important for the correct decision of discontinuing contact precautions (including single-room isolation) for suspected MRSA carriers. It is known that isolation precautions may have a negative impact on patient care due to the psychological effects of isolation, social isolation, less communication and information provision and direct negative effect on quality of care [14, 15] .
The economic advantages of using modern rapid MRSA diagnostic techniques compared to a culture-based strategy were demonstrated in a recent study [16] . Although the implementation of rapid MRSA screening is associated with increased laboratory expenses for equipment and consumables, the present study found a significant net cost-effectiveness of performing rapid MRSA screening. In our study, the GX MRSA gave greater savings compared to the MAX MRSA related to the benefits of on-demand rather than batch testing in our organizational structure. This illustrates the importance of laboratory organization in delivering the most effective infection prevention outcomes. Our study was performed in an area with very low MRSA prevalence, and these results and potential cost savings might be different in settings with a higher MRSA prevalence where fewer isolation days might have been saved.
In conclusion, this study found overall good agreement between the GX MRSA and MAX MRSA assays. Both assays had a high NPV, which is important for the management of patients in a low-prevalence setting. In our routine laboratory organization, GX MRSA had the lowest LTAT with an average of 2.9 h, which was able to support significant net hospital savings and minimize unnecessary isolation for patients.
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